Shin Sangjin, Shin Young-jeon, Ki Moran
Department of Health Care Management and Policy, Seoul National University, School of Public Health, Seoul, Korea.
J Korean Med Sci. 2008 Apr;23(2):176-84. doi: 10.3346/jkms.2008.23.2.176.
An economic evaluation of Haemophilus influenzae type b (Hib) immunization was conducted to examine whether Hib immunization should be included in Korea's national immunization program. The costs and benefits included direct and indirect values and an estimation of the economic efficiency. We determined that a universal Hib immunization program in Korea would prevent 17 deaths and 280 invasive Hib cases. When we assumed the one Hib immunization cost as 26,000 won, the national Hib immunization would cost 34.6 billion won. Costs for various Hib diseases were estimated at 26.8 billion won (11.8 billion won from direct costs and 14.9 billion won from indirect costs). A benefit-cost ratio of 0.77 showed that the economic efficiency of the integration of Hib immunization in Korea is low because of the low incidence rate of Hib disease and high price of vaccine. However, if the Hib immunization cost decrease to less than 20,000 won, a benefit-cost ratio increase to 1.0 and above, integrating Hib immunization into the national immunization program with economic efficiency can be considered.
对b型流感嗜血杆菌（Hib）免疫接种进行了一项经济评估，以研究Hib免疫接种是否应纳入韩国的国家免疫规划。成本和效益包括直接和间接价值以及经济效率的估计。我们确定，韩国的全民Hib免疫接种计划将预防17例死亡和280例侵袭性Hib病例。假设一剂Hib疫苗的成本为26000韩元，全国Hib免疫接种的成本将为346亿韩元。各种Hib疾病的成本估计为268亿韩元（直接成本118亿韩元，间接成本149亿韩元）。0.77的效益成本比表明，由于Hib疾病发病率低和疫苗价格高，韩国将Hib免疫接种纳入国家免疫规划的经济效率较低。然而，如果Hib免疫接种成本降至20000韩元以下，效益成本比将升至1.0及以上，则可以考虑将Hib免疫接种纳入具有经济效率的国家免疫规划。
